Ep. 109 - What's Next for Novartis? Plus: AACR, Merck KGaA
BioCentury This Week
00:00
TGF Beta Blocker
T g f bada is one of the oldest cancer targets, and this combination breathed new life into the target. The other thing i think is very interesting is that they have decided to go for more solid, smaller bets rather than betting the farm on something big. And strategically, fresh in light of what we heard about nevada's to day, got to make you wonder if we're going to start hearing from more of the big farmers about strategic shifts or how to manage their pipe line.
Transcript
Play full episode
